Brief: Elevation Oncology Reports Second Quarter 2022 Financial Results
04/08/2022 12:51
Aug 4 (Reuters) - Elevation Oncology:
* ELEVATION ONCOLOGY REPORTS SECOND QUARTER 2022 FINANCIAL
RESULTS
AND HIGHLIGHTS RECENT COMPANY PROGRESS
* ELEVATION ONCOLOGY INC - AS OF JUNE 30, 2022, COMPANY HAD
CASH,
CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALING $122.5
MILLION
* ELEVATION ONCOLOGY INC - NET LOSS FOR Q2 2022 WAS $19.9
MILLION,
COMPARED TO $5.1 MILLION FOR Q2 2021
* ELEVATION ONCOLOGY INC - CASH RUNWAY INTO 2024
Source text for Eikon: ID:nPn1RWyFga
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Elevation Oncology
See all newsBrief: Elevation Oncology Terminates License Agreement With CSPC Megalith Biopharmaceutical
U.S. RESEARCH ROUNDUP- Crane, Ryder System, Terex
Brief: Elevation Oncology Says Concentra To Buy Elevation Oncology For $0.36 Per Share Plus CVR
Elevation Oncology Inc expected to post a loss of 19 cents a share - Earnings Preview
Brief: Elevation Oncology Inc - To Prepay Term Loan Under Loan & Security Agreement Dated July 27, 2022 - SEC Filing